University of Virginia School of Medicine, UVA Center for Diabetes Technology, Ivy Translational Research Building, 560 Ray C. Hunt Drive, Charlottesville, VA 22903-2981, USA.
Trends Endocrinol Metab. 2019 Jul;30(7):432-444. doi: 10.1016/j.tem.2019.04.008. Epub 2019 May 28.
Arguably, diabetes mellitus is one of the best-quantified human conditions: elaborate in silico models describe the action of the human metabolic system; real-time signals such as continuous glucose monitoring are readily available; insulin delivery is being automated; and control algorithms are capable of optimizing blood glucose fluctuation in patients' natural environments. The transition of the artificial pancreas (AP) to everyday clinical use is happening now, and is contingent upon seamless concerted work of devices encompassing the patient in a digital treatment ecosystem. This review recounts briefly the story of diabetes technology, which began a century ago with the discovery of insulin, progressed through glucose monitoring and subcutaneous insulin delivery, and is now rapidly advancing towards fully automated clinically viable AP systems.
可以说,糖尿病是人类条件中被量化得最好的疾病之一:详细的计算机模型描述了人体代谢系统的作用;实时信号,如连续血糖监测,随时可用;胰岛素输送正在自动化;控制算法能够优化患者自然环境中的血糖波动。人工胰腺 (AP) 现在正在过渡到日常临床使用,并依赖于将患者纳入数字治疗生态系统的设备之间的无缝协同工作。这篇综述简要回顾了糖尿病技术的发展历程,该技术始于一个世纪前胰岛素的发现,经过血糖监测和皮下胰岛素输送的发展,现在正在迅速向全自动临床可行的 AP 系统推进。